IN THE CLAIMS

1. (Original) A method of treating a patient suffering from neuropathy which comprises treating said patient with an effective amount of a cGMP PDE5 inhibitor, with the proviso that the inhibitor is not a:
   i) substituted 5-(3-pyridyl)pyrazolo[4,3-d]pyrimidin-7-one,
   ii) substituted 2-(3-pyridyl)-4a,5-dihydroimidazo[5,1-*f*][1,2,4]triazin-4(3*H*)-one, or
   iii) substituted 2-phenylpurin-6-one or a substituted 2-(3-pyridyl)purin-6-one,

   for treating peripheral diabetic neuropathy.

2. (Cancel)
3. (Cancel)
4. (Cancel)
5. (Cancel)
6. (Cancel)
7. (Cancel)
8. (Cancel)
9. (Cancel)
10. (Cancel)
11. (Cancel)
12. (Cancel)
13. (Cancel)
14. (Cancel)
15. (Cancel)
16. (Cancel)
17. (New) A combination comprising a therapeutically effective amount of a cGMP PDE5 inhibitor and a therapeutically effective amount of pregabalin or gabapentin.

18. (New) A pharmaceutical composition comprising:
    a therapeutically effective amount of a first compound said compound being a cGMP PDE5 inhibitor;

a therapeutically effective amount of a second compound said second compound being pregabalin or gabapentin; and

a pharmaceutically acceptable excipient, diluent or carrier. .

19. (New) The pharmaceutical composition as recited in claim 18 wherein the inhibitor has an IC50 at less than 100 nanomolar.

20. (New) The pharmaceutical composition as recited in claim 19 wherein the inhibitor has a selectivity ratio in excess of 100.

21. (New) The pharmaceutical composition as recited in claim 18 wherein the inhibitor is sildenafil, or pharmaceutically acceptable salts thereof.

22. (New) The pharmaceutical composition as recited in claim 18 wherein said second compound comprises a therapeutically effective amount of pregabalin.

23. (New) The pharmaceutical composition as recited in claim 18 wherein said second compound comprises a therapeutically effective amount of gabapentin.

24. (New) The pharmaceutical composition as recited in claim 22 or 23 wherein the inhibitor has an IC50 at less than 100 nanomolar.

25. (New) The pharmaceutical composition as recited in claim 22 or 23 wherein the inhibitor has a selectivity ratio in excess of 100.

26. (New) The pharmaceutical composition as recited in claim 22 or 23 wherein the inhibitor is sildenafil, or pharmaceutically acceptable salts thereof.

27. (New) A method of treating a patient suffering from neuropathy which comprises administering a patient in need of therapy thereof a therapeutically effective amount of a combination of a cGMP PDE5 inhibitor and pregabalin or gabapentin.

28. (New) A method as recited in claim 27 wherein the neuropathy is diabetic polyneuropathy.

29. (New) A method as recited in claim 27 or 28 wherein the inhibitor is administered orally

30. (New) A method as recited to claim 29 wherein the inhibitor has an IC50 at less than 100 nanomolar.

31. (New) A method as recited in claim 29 wherein the inhibitor has a selectivity ratio in excess of 100.

32. (New) A method as recited in claim 29 wherein the inhibitor is sildenafil, or pharmaceutically acceptable salts thereof.

33. (New) A method according to claim 29 wherein pregabalin is administered.

34. (New) A method according to claim 29 wherein gabapentin is administered.